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ABSTRACT
The diagnostic criteria used to identify patients suffering from
polycystic ovary syndrome remain controversial. The present pro-
spective longitudinal follow-up study was designed to identify
whether certain criteria assessed during standardized initial screen-
ing could predict the response to ovulation induction with clomiphene
citrate (CC) in 201 patients presenting with oligomenorrhea or am-
enorrhea and infertility. Serum FSH levels were within the normal
range (1–10 IU/L), and all patients underwent spontaneous or
progestin-induced withdrawal bleeding. Initial CC doses were 50 mg
daily for 5 days starting on cycle day 3. In the case of an absent
response, doses were increased to 100 and 150 mg daily in subsequent
cycles. First ovulation with CC was used as the end point. After a
complete follow-up (in the case of a nonresponse, at least 3 treatment
cycles with daily CC doses up to 150 mg), 156 patients (78%) ovulated.
The free androgen index (FAI 5 testosterone/sex hormone-binding
globulin ratio), body mass index (BMI), cycle history (oligomenorrhea
vs. amenorrhea), serum androgen (testosterone and/or androstenedi-
one) levels, and mean ovarian volume assessed by transvaginal sonog-
raphy were all significantly different (P , 0.01) in responders from
those in nonresponders. FAI was chosen to be the best predictor in
univariate analysis. The area under the receiver operating charac-
teristics curve in a multivariate prediction model including FAI, BMI,
cycle history, and mean ovarian volume was 0.82.
Patients whose ovaries are less likely to respond to stimulation by
FSH due to CC treatment can be predicted on the basis of initial
screening characteristics, such as FAI, BMI, cycle history (oligomen-
orrhea or amenorrhea), and mean ovarian volume. These observa-
tions may add to ongoing discussion regarding etiological factors
involved in ovarian dysfunction in these patients and classification of
normogonadotropic anovulatory infertile women. (J Clin Endocrinol
Metab 83: 2361–2365, 1998)
CHRONIC anovulation is a frequent cause of infertility,and approximately 80% of these patients present with
serum FSH and estradiol levels within the normal range
(WHO group 2) (1). The antiestrogen clomiphene citrate (CC)
is considered to be a successful treatment strategy in these
patients. It has been documented that approximately 70–
80% of these women will become ovulatory (2–7), whereas
40–50% of ovulatory women will conceive (3, 5).
Polycystic ovary syndrome (PCOS), usually referred to as
chronic hyperandrogenic anovulation, represents a distinct
proportion of WHO group 2 anovulatory patients. It is un-
certain to what extent PCOS patients are particularly prone
to remain resistant to CC medication (8, 9). Discussion con-
tinues regarding the validity of criteria used to diagnose
PCOS (10) as well as its relevance for clinical practice. We
have previously demonstrated that a distinct overlap exists
between endocrine and ultrasound features used by various
researchers (11). If strict criteria are used for PCOS diagnosis,
a large heterogeneous group of normoestrogenic patients
will remain unclassified.
Thirty-five years after its first clinical introduction (12), CC
still remains the first line treatment strategy in normogona-
dotropic anovulatory patients. Although rising serum FSH
levels due to CC interference with estrogen negative feed-
back may be held responsible for stimulating follicle growth
(13–15), other mechanisms of action have also been proposed
(9, 16). A significant proportion of treated women, however,
do not respond. The aim of this study was to investigate
whether clinical, endocrine, and sonographic characteristics
during initial screening of normogonadotropic anovulatory
infertile women may predict the ovarian response to CC
medication. This approach may help to define conditions that
prevent the ovary from responding to stimulation by in-
creased FSH levels and to further classify WHO group 2
anovulatory patients.
Subjects and Methods
Subjects and study design
Approval for this study was obtained from the human subject com-
mittee of the Dijkzigt Hospital/Erasmus University. Between February
1993 and September 1996, 201 patients presenting with oligomenorrhea
(interval between vaginal bleeding .35 days and ,6 months) or am-
enorrhea (bleeding interval .6 months) and infertility were recruited.
Informed consent was obtained from all participants. All subjects were
referred directly by their general practitioner to our infertility unit. None
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had received previous ovulation induction medication. Additional in-
clusion criteria were serum FSH levels within normal limits (1–10 IU/L)
(1, 17), spontaneous menses or a positive bleeding response to proge-
stagen withdrawal, normal serum PRL and THS levels, body mass index
(BMI; weight divided by the square of the patients height) more than 18,
and age less than 40 yr.
Clinical, endocrine, and sonographic screening was carried out before
initiation of CC therapy. Clinical screening included infertility and cycle
history, BMI, previous medication, and/or surgery. Endocrine screening
included serum assays of FSH, PRL, TSH, LH, estradiol, androstenedi-
one (AD), testosterone (T), sex hormone-binding globulin (SHBG), cor-
tisol, and dehydroepiandrosterone sulfate. Fasting blood samples were
taken randomly between 0800–1000 h before the initiation of therapy.
Venous blood samples were centrifuged within 2 h after withdrawal and
were stored at 220 C until assayed. Transvaginal sonographic screening
included assessment of the ovarian stroma echogenicity (arbitrarily clas-
sified from 1–3), ovarian volume (milliliters), and total number of fol-
licles (both ovaries), as described previously (11, 18). Serum LH and FSH
levels were measured by immunoradiometric assay (Medgenix, Fleurus,
Belgium), and T, AD, SHBG, and dehydroepiandrosterone sulfate were
determined using RIA kits (Diagnostic Products Corp., Los Angeles,
CA), as described previously (19, 20).
The treatment schedule and assessment of ovarian response were as
follows. CC medication was initiated on day 3 after spontaneous or
progestagen-induced withdrawal bleeding. The starting dose was 50
mg/day, orally, for 5 subsequent days. In the case of an absent response,
daily doses were increased by 50 mg in the next cycle to a maximum dose
of 150 mg/day in the following cycle. If ovulation occurred, the dose
remained unaltered during subsequent cycles. First ovulation was used
as the end point. The duration of follow-up for all patients included in
the study was at least three treatment cycles. Ovulation was assessed by
midluteal serum progesterone measurement (levels .25 nmol/L indi-
cating ovulation) combined with transvaginal sonographic monitoring
of follicle growth until the appearance of a preovulatory follicle (mean
diameter, $18 mm) and subsequent follicle rupture, or by biphasic basal
body temperature charts. Responders were defined as patients who
ovulated during CC therapy, independent of the dose administered. The
number of treatment cycles and the CC dose in which first ovulation
occurred were recorded. Clomiphene-resistant anovulation (CRA) was
defined as patients who do not ovulate despite receiving maximum
treatment doses of 150 mg/day.
Data analysis
Distribution of characteristics in patient groups is presented as the
mean 6 sd. We used the Mann-Whitney U test and the Wilcoxon rank
sum W test for exploratory comparison of initial parameters between
responders and nonresponders. The univariate and multivariate relation
with response to CC was assessed using logistic regression analysis. The
following parameters were used in the analysis: BMI, free androgen
index (FAI; T 3 100/SHBG), serum T and/or AD concentrations, serum
LH levels, cycle history (oligomenorrhea or amenorrhea), cycle duration
in case of oligomenorrhea, mean ovarian volume, and follicle number.
Backward stepwise elimination was used for the multivariate logistic
analysis of prediction of patients being CRA, and P # 0.10 was used as
a cut-off level for elimination of nonsignificant predictors from the
prognostic model. The area under the receiver operating characteristics
(ROC) curve (AUC) was used to assess the discriminative ability of the
logistic models. The AUC gives the proportion of all pairs of patients
(each pair consisting of one patient without and the other patient with
a response to CC) in which the model predicts a higher probability of
no response for the patient without response. The Statistical Analysis
System program (SAS Institute, Cary, NC) was employed for data
analysis.
Because selection and estimation were performed for 8 potential
predictors on a dataset with only 45 events (CRAs), correction for over-
fitting was performed (21). The internal validity of the prognostic model
was tested by a bootstrapping method in which the selection and esti-
mation process was repeated 200 times. Each of these repetitions con-
sisted of creating a new dataset (bootstrap sample) by drawing cases
with replacement from the original data. The backward stepwise elim-
ination process was performed on this dataset, yielding a set of selected
predictors and parameter estimates (21, 22). Resulting model estimates
of each bootstrap sample were evaluated on the original data, and a
shrinkage factor was estimated to correct for statistical overoptimism.
The Hosmer-Lemeshow goodness of fit test (23) has been used to
check for lack of fit of the final model. The logistic coefficients that
were corrected by the shrinkage factor have been translated into an
easy to use score chart. The scores were calculated by multiplying the
shrunk coefficients by 10 and rounding them off to the nearest whole
number.
Results
The number of patients who did or did not ovulate after
CC medication in increasing doses of 50, 100, and 150 mg
daily are depicted in Fig. 1. Forty-five patients (22.5% of the
overall study group) remaining anovulatory were consid-
ered having CRA. A total of 432 cycles were analyzed.
From the total study group of 201 women, 91 (46%) were
considered obese (BMI .26), 101 patients (50%) presented
with an elevated FAI (.4.5), 85 patients (42%) presented with
hyperandrogenemia (T $3.2 nmol/L and/or AD $16.3
nmol/L) (11, 19), and in 125 patients (66%) polycystic ovaries
(mean ovarian volume $10.8 mL and/or mean follicle num-
ber per ovary $10) (11, 18) were diagnosed. Finally, 105
patients (54%) presented with elevated LH ($7.0 IU/L) se-
rum levels (11, 19).
In Table 1, clinical, endocrine, and ultrasound character-
istics are presented for the overall study group and sepa-
rately for patients who did or did not ovulate after CC med-
ication. Forty-four percent of patients presenting with
amenorrhea (17 of 39) were considered to have CRA, whereas
only 17% (28 of 162) of patients with oligomenorrhea showed
no response. Statistical significance in univariate analysis
with logistic regression analyses and ROC AUC of the initial
parameters are depicted in Table 2. The AUCs for FAI and
BMI were the highest (0.76 and 0.70, respectively). The ROC
curve with the best performance (FAI) and that with the
poorest performance (serum LH) are shown in Fig. 2.
Of the 201 patients, 187 had complete data on the variables
used in the multivariate analysis. Using the backward elim-
ination procedure, 4 variables were selected in the final mod-
el: 1) FAI, 2) BMI, 3) cycle history (oligomenorrhea or am-
enorrhea), and 4) mean ovarian volume. By using the
FIG. 1. Distribution of normogonadotropic oligomenorrheic or amen-
orrheic infertile women who do or do not ovulate after CC induction
of ovulation in incremental daily doses of 50, 100, or 150 mg for 5
subsequent days. A total of 45 women (22.5% of the overall study
group) remain anovulatory.
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combined information of these 4 variables, the AUC further
improved to 0.82 (Table 2 and Fig. 2). The bootstrap proce-
dure revealed that these 4 predictors were selected in over
two thirds of the bootstrap samples, whereas all other can-
didate variables were selected in less than half of the samples,
which illustrates the stability of the final model. The shrink-
age factor was estimated from the bootstrap procedure to be
0.82, indicating that when this study is replicated many
times, the resulting coefficients of the final multivariate
model are, on the average, 18% smaller. This was incorpo-
rated in the calculation of the scores. The scores for different
parameters are depicted in Table 3, and resulting probability
scores for patients remaining anovulatory after CC medica-
tion are shown in Fig. 3. The Hosmer-Lemeshow goodness
of fit test showed no lack of fit of the final model to the data
(P 5 0.3).
Discussion
It may be helpful for further classification of normogonado-
tropic anovulatory infertility and for evaluating pathophysio-
logical factors involved in ovarian abnormalities in these pa-
tients to study in a longitudinal fashion whether initial
screening parameters may predict success, failure, or compli-
cations of induction of ovulation. The present study was de-
signed to investigate as a first step whether ovarian response
after CC medication could be predicted. It is established in the
literature that approximately 75% of patients will ovulate, and
less than 50% of the total population will conceive after CC as
first line medication. If patients remaining anovulatory despite
CC therapy could be identified beforehand, ineffective and
TABLE 1. Clinical, endocrine, and ultrasound characteristics (mean 6 SD) during initial screening of 201 normogonadotropic
oligomenorrheic or amenorrheic infertile women, and separated for patients who do (responders) or do not ovulate (CRA) after CC
induction of ovulation
Screening parameters Overall group(n 5 201)
CC responder
(n 5 156; 77.5%)
CRA
(n 5 45; 22.5%) P value
a
Clinical
Age (yr) 28 6 4.4 28 6 4.5 27.5 6 4.5 NS
Primary infertility (n) 145 (72%) 110 (71%) 35 (78%) NS
Amenorrhea (n) 39 (19%) 22 (14%) 17 (38%) 0.0004
Bleeding interval (days, in case of oligomenorrhea) 79 6 62 70 6 56 113 6 72 ,0.0001
BMI (kg/m2) 26.6 6 6.2 25.5 6 5.8 30.0 6 6.6 0.0001
Endocrine
T (nmol/L) 2.3 6 0.9 2.1 6 0.9 2.7 6 1.0 0.001
AD (nmol/L) 16.5 6 7.8 15.3 6 6.5 20.5 6 10.2 0.001
SHBG (nmol/L) 53 6 31.7 57 6 32.5 38.3 6 23.8 ,0.0001
FAI (T 3 100/SHBG) 5.9 6 4.3 4.9 6 3.4 9.3 6 5.3 ,0.0001
LH (IU/L) 7.8 6 4.3 7.8 6 4.3 8.2 6 4.6 NS
FSH (IU/L) 4.4 6 1.4 4.5 6 1.4 4.2 6 1.4 NS
E2 (pmol/L) 282 6 233 296 6 195 234 6 78 NS
DHEAS (mmol/L) 7.9 6 3.8 7.9 6 3.7 7.9 6 4 NS
TVS
Total stroma scoreb 3.0 6 1.0 2.8 6 1.3 3.3 6 1.1 0.006
Mean ovarian vol (mL) 10.0 6 4.4 9.2 6 5.7 12.2 6 5.8 0.0007
Mean follicle no. 11.5 6 5 11 6 6 12 6 5 NS
a Comparison of CC responders vs. CRA (by Mann-Whitney U test).
b Arbitrarily defined as one to three per ovary (both ovaries added).
TABLE 2. Univariate and multivariate logistic regression
analyses with score test and area under the ROC curve (AUC) of
initial clinical, endocrine, and sonographic screening parameters in
201 normogonadotropic oligomenorrheic or amenorrheic infertile
women for the prediction of patients remaining anovulatory after
CC induction of ovulation
Parameters P value AUCa
Univariate analyses
FAI (T 3 100/SHBG) ,0.0001 0.76
BMI (kg/m2) ,0.0001 0.70
Mean ovarian vol 0.0001 0.67
Hyperandrogenemia (elevated T and/or AD) 0.0007 0.64
Oligomenorrhea or amenorrhea 0.0005 0.62
Mean follicle no. 0.1 0.58
Bleeding interval in case of oligomenorrhea 0.42 0.53
LH (IU/L) 0.5 0.52
Multivariate analysis
Prediction model for CRAb 0.82
a Area under the ROC curve.
b Combination of four initial screening parameters: FAI, BMI, cycle
history (oligomenorrhea or amenorrhea), and mean ovarian volume.
FIG. 2. ROC curve of serum LH concentration, FAI, or the prediction
model (FAI, BMI, cycle history, and mean ovarian volume combined)
for predicting CRA in a total group of 201 normogonadotropic oligo-
menorrheic or amenorrheic infertile women.
RESPONSE PREDICTORS OF CLOMIPHENE OVULATION INDUCTION 2363
 at Medical Library Erasmus MC on December 11, 2006 jcem.endojournals.orgDownloaded from 
time-consuming CC treatment could be prevented. This may be
helpful, particularly for women of advanced reproductive age.
Further studies, however, are required to investigate whether
alternative primary treatment options are cost effective. More-
over, etiological factors involved in ovarian dysfunction could
be identified in this heterogeneous patient group, as subjects
whose ovaries will or will not respond to increased FSH stim-
ulation may be differentiated.
For this first analysis of response to CC medication we de-
cided to focus on ovulation rather than conception. Ovulation
is biologically relevant and most closely connected to the de-
sired effects of CC medication. Analysis of conception as the
end point requires a comprehensive study of other potential
confounders, such as tubal factor, sperm factor, and endome-
trial function. Four initial screening parameters (FAI, BMI,
mean ovarian volume, and cycle history) could be identified,
predicting patients remaining anovulatory after CC medica-
tion. A combination of these parameters showed good predic-
tive power, with a ROC AUC of 0.82. Several studies have been
published recently regarding the use of a similar multivariate
model for predicting chances for conception in infertile patients
with regular cycles (24–26). Various researchers have investi-
gated the predictive value of clinical and endocrine screening
parameters for the response to CC. Only a positive correlation
between body weight and the dose of CC required to induce
ovulation has been established (8, 27). A recent study has in-
dicated that increased BMI is the only initial parameter that is
significantly different between responders and nonresponders
(28). To our knowledge this is the first time a multivariate
prediction model has been applied in the treatment of anovu-
latory infertility. We could demonstrate that patients suffering
from amenorrhea, obesity, increased ovarian volume, and el-
evated androgen levels (a complex of signs, symptoms, and
ultrasound and endocrine findings frequently referred to as
PCOS) are most likely to remain anovulatory after CC induction
of ovulation. A model can be used to predict chances for an
individual patient to remain anovulatory by calculating a total
score on the basis of these initial screening characteristics. Fur-
ther studies should validate the prediction model in a new
group of patients. The present study also suggests that LH
concentrations do not predict ovarian response after CC med-
ication in accordance with recent observations by others (28).
These data oppose the concept that elevated LH is implemented
in ovarian dysfunction in these patients (29). However, the
assessment of LH levels in anovulatory patients is problematic
due to effects of timing, the immunoassays used, and the pul-
satile nature of LH release (30).
Together, these observations suggest that obese hyperan-
drogenic women are less likely to respond to increased stim-
ulation by FSH, suggesting that these factors are instrumen-
tal in follicle maturation arrest (31) and an increased FSH
threshold (6). The correlation between BMI and ovarian re-
sponse after CC treatment suggests that much emphasis
should be focused on weight reduction. However, it should
be realized that scientific proof for this approach is lacking,
and that weight reduction may not necessarily result in nor-
mal response. Previous work from our group demonstrated
indeed that long term androgen medication in female to male
transsexuals induces polycystic ovary morphology, charac-
terized by increased ovarian size, augmented follicle num-
ber, and stroma hyperplasia (32). Assessment of steroid
levels in follicle fluid obtained from polycystic ovaries sug-
gested that disturbed dominant follicle selection in hyperan-
drogenic patients may result from disrupted enhancement of
FIG. 3. Score chart and the probability for a given woman to remain
anovulatory after CC induction of ovulation.
TABLE 3. Score charts of four initial screening parameters of the
final model for prediction of patients remaining anovulatory after
CC induction of ovulation in normogonadotropic oligomenorrheic or
amenorrheic infertile women (total scores, 0–53)
Initial screening parameters Scorea
FAI (T 3 100/SHBG)
,2 0
2–3 1
3–4 2
4–5 3
5–6 5
6–8 6
8–11 10
.11 14
BMI (kg/m2)
,20 0
20–21.5 2
21.5–23 3
23–25 4
25–27 6
27–31 8
31–35 12
.35 15
Mean ovarian vol (mL)
,6 0
6–7 2
7–8 2
8–9 3
9–11 5
11–13 6
13–16 9
.16 11
Cycle history
Oligomenorrhea 0
Amenorrhea 13
Total score —
a Encircle the scores related to each category of the screening pa-
rameters and add them together. Correspond the total score to the
score chart (Fig. 3). As an example, a new amenorrheic patient had
the following findings: FAI 5 8.7, BMI 5 29.4, and mean ovarian
volume 5 13 ml. Scores are 10 for FAI, 8 for BMI, 9 for mean ovarian
volume, and 13 for having amenorrhea. The total score is 40, and the
corresponding probability to be CRA is 65%.
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FSH-induced aromatase activity (33). This could be due to
intraovarian dysregulation of FSH action, which precludes a
normal response (i.e. follicle growth and ovulation) after
incremental FSH levels elicited by CC medication. Factors
involved may include locally produced growth factors or
insulin resistance (34, 35). Alternative explanations for a non-
response after CC may include 1) an abnormal hypothalam-
ic/pituitary response to steroid feedback resulting in an in-
sufficient rise in FSH after CC, 2) individual differences in the
FSH isohormone profile resulting in discrepancies in bioac-
tive FSH concentrations despite similar immunoreactive FSH
levels, 3) additional, as yet unidentified, mechanisms re-
sponsible for at least part of CC actions. Recently reported
CC-induced changes in the insulin-like growth factor system
(16) may be relevant in this regard. It may be speculated that
improved insight into any of these factors (intraovarian dys-
regulation (36), hypothalamic/pituitary dysfunction (37),
FSH heterogeneity (38), or the insulin-like growth factor sys-
tem (34)) may eventually result in additional predictors of the
CC response. Further studies focusing on insulin resistance
may also be of interest, as recent reports suggest that ovarian
dysfunction may improve after the use of insulin-sensitizing
agents (39). Preliminary observations (Imani, B. and Fauser,
B. C. J. M., unpublished observations) suggest that fasting
insulin levels are increased in CRA patients. It requires fur-
ther study to clarify whether insulin resistance is a deter-
mining factor in an abnormal response to FSH independent
from androgen concentrations, as the majority of studies
propose that insulin resistance is associated with PCOS
through increased thecal cell androgen production (35).
In conclusion, this study demonstrates that it is possible to
predict patients remaining anovulatory during CC induction of
ovulation using criteria that are directly associated with PCOS,
predominantly obesity and hyperandrogenemia. Further stud-
ies should establish whether the occurrence of pregnancies after
CC medication can also be predicted and whether similar fac-
tors are involved. The identification of initial characteristics that
predict the ovarian response to ovulation induction therapy
may help to further classify the heterogeneous group of nor-
mogonadotropic anovulatory infertile women. The present
study suggests that hyperandrogenemia and obesity are crucial
in inducing ovarian abnormalities that are less likely to respond
to increased stimulation by FSH.
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